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A B S T R A C TObjectives: This article presents a methodological framework for
developing health economic models of whole systems of disease
and treatment pathways to inform decisions concerning resource
allocation—an approach referred to as ‘‘Whole Disease Modeling.’’
This system-level approach can provide a consistent mathematical
infrastructure for the economic evaluation of virtually any interven-
tion across a disease pathway. Methods: The framework has been
developed for cancer but is broadly generalizable to other diseases. It
has been informed by pilot work, a systematic review of economic
analyses, a qualitative examination of model development processes,
and other literature from the fields of operational research, statistics,
and health economics. Results: The framework is built on three
principles: 1) the model boundary and breadth should capture all
relevant aspects of the disease and its treatment—from preclinical
disease through to death, 2) the model should be developed such that
the decision node is conceptually transferable across the model, andnt matter Copyright & 2012, International Society
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.1016/j.jval.2012.07.008
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ondence to: Paul Tappenden, Health Economics
eld, Regent Court, 30 Regent Street, Sheffield S1 43) the costs and consequences of service elements should be structu-
rally related. A generalized process for developing Whole Disease
Models is presented. Discussion: Although this approach involves a
nontrivial investment of time and resource, its value may be realized
when 1) multiple options for service change require economic analy-
sis at a single time point, 2) a disease service changes rapidly and the
model can be reused, 3) current services within a pathway have not
been subjected to economic analysis, 4) upstream events are expected
to have important downstream effects, or 5) simple cost-utility
decision rules fail to reflect the complexity of the decision-makers’
objectives.
Keywords: cancer, decision models, economic analysis, methodology,
microsimulation.
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The role of health economic evaluation is to inform decisions
concerning the allocation of scarce health care resources. Its
principal concern is to help decision makers make better deci-
sions through the explicit examination of economic trade-offs,
with the ultimate goal of maximizing health- or welfare-related
outcomes. Where competing alternatives exist, economic analy-
sis is intended to provide a means of determining whether one
state of the world is preferable to another. Most applied economic
evaluations adopt some form of cost-effectiveness analysis; this
extra-welfarist approach can be theoretically represented as a
constrained optimization problem in which the objective is to
maximize health outcomes given some budget constraint [1]. In
principle, mathematical programming may be used to determine
the portfolio of health interventions that are expected to produce
the greatest health gain. Owing, however, to imperfect informa-
tion and the resources required to undertake such an exercise,
this has not proved feasible. Consequently, applied economic
evaluation represents a departure from this formulation of the
problem. In practice, economic evaluation is ‘‘piecewise’’ innature, involving estimating expected costs and health outcomes
of interventions at an isolated point within a broader pathway of
care, with cost-effectiveness determined through reference to
some acceptable willingness-to-pay threshold or threshold range.
Although this piecewise approach is feasible and has been
applied to directly inform a large number of policy decisions, in
particular those addressed by the National Institute for Health and
Clinical Excellence and similar agencies elsewhere [2–4], it is
subject to certain limitations that may subvert the original inten-
tions of economic evaluation. First, there remains an ongoing
debate on the appropriateness of using a threshold-based decision
rule and whether its repeated use will lead to a health-maximizing
situation [5–9]. Some commentators have argued that the basis of
economic evaluation is not an economic one—that it does not
fully address questions of opportunity cost [6], because the arti-
ficial separation of the threshold from the budget means that the
economic analysis does not explicitly consider either the resource
constraint or the requirement for disinvestment. Other economic
approaches that jointly consider investment and disinvestment
decisions exist [6,7,10,11]; however, their use is less common in
practice. Irrespective of which approach one considers to be thefor Pharmacoeconomics and Outcomes Research (ISPOR).
and Decision Science, School of Health and Related Research,
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of estimates of costs and health outcomes. Second, restricting the
scope of the economic analysis to a single decision point means
that other adoption decisions elsewhere in the disease pathway,
and their knock-on impacts, are often treated as being indepen-
dent of the decision problem under consideration. For example,
the cost-effectiveness of a cancer screening program is dependent
not only on the effectiveness and costs of the screening program
itself but also on the costs and benefits of downstream cancer
services. Although many economic analyses attempt to capture
such downstream impacts, the cost-effectiveness of health inter-
ventions may also be influenced by the impact of upstream
decisions. For example, launching a cancer screening program
may shift the stage distribution of patients at diagnosis, thereby
leading to different profiles of costs and consequences for down-
stream services such as follow-up after surgical resection. The
third problem is more subtle and concerns how models are
developed. The process of model development is one in which
the modeler, together with other stakeholders, makes decisions
concerning what is relevant to a particular decision problem.
These manifest as decisions concerning what should be included
in the model, what should be excluded, and how those included
phenomena should be conceptually and mathematically repre-
sented. In recent years, considerable effort has been afforded to
the development of best practice guidelines for the development
of decision-analytic models [12,13]. Coupled with the introduction
of standard reference cases [14–16], this has to some degree
resulted in a more ‘‘level playing field’’ for the appraisal of
economic models through a reduction of methodological hetero-
geneity within the particular health jurisdictions in which these
apply. Although this should ensure that the methods and report-
ing of an economic model adhere to certain accepted principles,
methods for the prospective conceptualization of a decision
problem and its translation to a quantitative health economic
model had until recently been neither prescribed nor suggested
(for a practical guide, see Kaltenthaler et al. [17]). There is
emerging evidence of variability surrounding how modelers deter-
mine what is relevant to a given decision problem [18]. This
absence of a common understanding of how relevance should be
determined can lead to inconsistencies between models that are
intended to represent similar decision problems [19].
In light of these concerns, this article puts forward a different
approach—Whole Disease Modeling—the notion of modeling the
‘‘bigger picture’’ by simulating whole disease and treatment
pathways within a single model. The distinguishing character-
istics of Whole Disease Modeling that set it apart from the
conventional piecewise approach are the wider disease-level
model scope of the model and its structural ability to evaluate
alternative interventions across the disease pathway within a
single mathematical framework. In cancer, this would involve
simulating the entire disease and treatment pathway from
preclinical disease through to diagnosis and referral, adjuvantFig. 1 – Illustrative representation of a Whotreatment, follow-up, potential recurrence, palliative treatment,
end-of-life care, and eventual death (see Fig. 1).
A Whole Disease Model is defined here as a model that1)leincludes preclinical and postdiagnostic pathways for indivi-
duals who may or may not develop a given disease at some
point in their lives, thus enabling the economic evaluation of
interventions for the prevention, early detection, and treat-
ment of a given disease across population subgroups within a
single consistent model;2) captures different service pathways from system entry to
discharge or death for specific subgroups of patients;3) represents events, costs and outcomes, and structural rela-
tionships between these to a level of detail such that the
decision node can be transferred across the modeled
pathway;4) allows for the economic evaluation of individual or multiple
service changes by using a range of alternative economic
decision rules (e.g., piecewise cost-utility analysis; Sendi,
Birch, and Gafni’s ‘‘step in the right direction’’ approach [6];
microlevel program-budgeting and marginal analysis (PBMA]
[7]; or disease-level constrained optimization).
These system-level modeling ideas are not entirely new, but
have seldom been applied in practice. Two system-level models
that can simultaneously evaluate interventions for disease pre-
vention and treatment are the Archimedes diabetes model [20,21]
and the CHD Policy Model [22]. These are both applied examples
of large-scale models developed initially within a single disease
area. The Whole Disease Modeling framework described here
differs in that it sets out the key principles for developing system-
level models to support economic analysis within any disease
area. The purpose of the article was to set out these principles, to
describe how they may be practically implemented within a
Whole Disease Model, and to suggest the circumstances whereby
the approach may be particularly valuable. The principles and
processes that comprise the framework have been informed by a
systematic review of economic analyses [19], pilot model devel-
opment with local and national decision makers [23,24], a
qualitative study of model development processes [18], and other
literature from the fields of operational research, statistics, and
health economics. Although the framework principles are
grounded in cancer service evaluation, they are intended to be
transferable to any disease area.The Principles of Whole Disease Modeling
The Whole Disease Modeling framework is centered on three key
principles, each of which should be considered before model
implementation. The main difference between piecewise eco-
nomic models and Whole Disease Models concerns the model’sDisease Model for colorectal cancer.
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within any model: model boundary, breadth, and depth (see
Fig. 2). This nomenclature has been used elsewhere, albeit with
different semantic interpretation [20,25,26]. Model boundary
relates to the populations represented within the model, that is,
the groups of entities that are singled out as the subject
of the part of reality that the model is attempting to represent.
Breadth concerns the extent to which phenomena that impinge
on the populations captured within the model boundary, and
their costs and consequences, are included and represented
within the model. In other words, breadth concerns how far
the model considers the downstream disease and service path-
ways for specific subgroups of patients. Model depth concerns
the level of detail or granularity through which relevant
disease- and treatment-related events, and their costs and con-
sequences, are captured within the model. Although model
boundary and breadth determine whether certain events are
included, depth concerns the level of detail to which they are
represented.
These concepts describe what the model is about, the popula-
tions whose experiences are reflected, the disease and service
pathways that are included or excluded, and how relationships
between included phenomena are represented. These concerns
are related to the usability and credibility of any health economic
model irrespective of its scope.
Framework principle 1: The model boundary and breadth
should capture all relevant aspects of the disease and its
treatment—from preclinical disease through to death
The first principle requires that the model boundary is defined at
the level of the general population. This is required because the
model boundary must encompass all relevant aspects of the
disease and its treatment from preclinical disease through to
diagnosis and referral, early treatment, follow-up and other typesOUTSIDE OF MODEL WORLD
MODEL WORLD
Model breadth
Mod
Preclinical 
disease Interventions De
Fig. 2 – Relationship between modeof monitoring, potentially curative treatments for metastases,
palliative treatments, end-of-life care, and eventual death. As
this form of model is intended to be structurally capable of
evaluating outcomes and costs for all individuals affected by
change across the cancer system, the partial representation of
the population, the disease, or the service pathways will infringe
this ability. The span of cancer services is broader than clinical
disease management, often also including disease prevention
and/or early detection. As such, the model boundary should
capture costs and consequences for individuals who consume
services but who do not have or may never develop the disease
under consideration. To capture events, costs, and outcomes
associated with services consumed by these groups (e.g. screen-
ing, diagnosis, surveillance of nonmalignant pathology), the
Whole Disease Model should always begin with a preclinical
natural history disease component.
A model’s breadth is related to its time horizon. Current
recommendations for economic evaluation require that the time
horizon should be sufficiently long to capture all differences in
costs and effects between options [27], usually implying the need
for a lifetime horizon for the population under consideration.
Nevertheless, if the goal of economic evaluation is to capture all
relevant differences in costs and outcomes, then capturing the
full breadth of the disease service is as important as the time
horizon itself. The omission of relevant aspects of the disease
service boundary and breadth has two negative consequences:
1) it will not be possible to evaluate options relating to aspects of
pathways that are not represented within the model and 2) the
options that can be evaluated will fail to capture upstream and
downstream impacts associated with the missing elements of
the system and may therefore produce misleading or erroneous
model results. In addition, some consideration should be given to
adopting a wider boundary to capture the impact of interventions
with cross-generational effects (e.g., identification of family
history).el boundary
ath
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that the decision node is conceptually transferable across the
model
Conventional health economic models typically use a single
decision node that, in reality, exists within a broader care path-
way. This usually limits the model’s use to the single decision
point. The second framework principle requires that individual or
multiple decision nodes can be transferred to any point in the
model at which choices concerning health interventions may be
considered. To illustrate this principle, consider a simplified
model of a hypothetical cancer pathway comprising nine con-
secutive groups of services: screening (s1), diagnosis (d1), surgical
excision (e1), adjuvant chemotherapy (a1), radiotherapy (r1),
follow-up (f1), metastasectomy (m1), palliative chemotherapy
(p1), and best supportive care (b1). Also assume that the model
output is defined as the lifetime incremental cost per quality-
adjusted life-year (QALY) gained. The expected system cost,
denoted C, is calculated as a function of costs across the serviceP
c(s1, d1, e1, a1, r1, f1, m1, p1, b1), whereas the expected system
QALY gain, denoted Q, is calculated as a function of the health
gains associated with each individual service component
P
q(s1,
d1, e1, a1, r1, f1, m1, p1, b1). Suppose a decision maker wanted to
assess the incremental cost-utility of surgical procedure e2, the
conventional piecewise model would place the decision node at
the point of surgery and estimate incremental cost-effectiveness
as a function of downstream interventions, thus ignoring the
influences of screening and diagnostic tests:
ICER ¼
P
cðe2, a1, r1, f1, m1, p1, b1Þ 
P
cðe1, a1, r1, f1, m1, p1, b1ÞP
qðe2, a1, r1, f1, m1, p1, b1Þ 
P
qðe1, a1, r1, f1, m1, p1, b1Þ
ð1Þ
This has two implications. First, surgical procedures e2 and e1
may exert differential influences on the costs and outcomes of
downstream interventions a1, r1, f1, m1, p1, and b1. For example, e2
may produce a more favorable disease-free survival (DFS) period
than does e1, which will affect the utilization, costs, and out-
comes of downstream treatments for relapsing patients. Thus,
the model boundary and breadth should be defined such that
these effects are captured within the objective function. Second,
changes to upstream services (particularly screening s1 and
diagnosis d1) may change the case mix of patients undergoing
surgery e1 or e2. Consequently, the narrow formulation of Eq. 1 is
inappropriate if upstream changes to s1 or d1 are likely. Instead,
the model should be evaluated according to the function of
system-level costs and outcomes (Eq. 2).
ICER ¼
P
cðs1, d1, e2, a1, r1, f1, m1, p1, b1Þ 
P
cðs1, d1, e1, a1, r1, f1, m1, p1, b1ÞP
qðs1, d1, e2, a1, r1, f1, m1, p1, b1Þ 
P
qðs1, d1, e1, a1, r1, f1, m1, p1, b1Þ
ð2Þ
Although conceptually the evaluation of service change across
the pathway involves repositioning the decision node around the
model, when implemented, it is the comparison of incremental
costs and benefits of competing whole service configurations that
is required. This wider model boundary therefore allows for the
simultaneous evaluation of multiple options, for example, s2, f2,
and b2.
Framework principle 3: The costs and consequences of service
elements should be structurally related
The third framework principle concerns model depth and
requires that the costs and consequences associated with service
elements are structurally related. In other words, not only must
each portion of the model be represented to an adequate level of
detail, but also the costs of services consumed should be
structurally related to the health outcomes that they generate.Drawing on the hypothetical model presented in Eq. 2, if costs C
are modeled as
P
c(s1, d1, e2, a1, r1, f1, m1, p1, b1) but total QALYs Q
are estimated directly as
P
q, the evaluation of any option for
service change becomes virtually impossible, because one would
struggle to estimate the impact of, say, a2 on Q (note this is a
common approach for modeling disease management and prog-
nosis in screening models [28]). Instead, aggregate system out-
comes and costs should be modeled as a function of the events
experienced by particular patient subgroups over the model time
horizon.
To capture this interdependence between events, costs, and
outcomes, the Whole Disease Model must segment certain
subgroups with differential prognoses and treatment pathways.
The obvious question then is ‘‘where to segment?’’ These choices
will differ between disease areas and according to the availability
of evidence; however, two considerations will be universally
required. First, prospective consideration is required regarding
the types of interventions that could be evaluated within the
Whole Disease Model. It is unnecessary to specify the exact
technologies or services upfront, but it is necessary to specify the
clinical intent of the type of intervention (e.g., chemotherapies to
increase DFS in population A). Second, some causal theory of
disease natural history or baseline risk is required to inform
modeled relationships between intermediate and final end points
to reflect the impact of the intervention on the segmented
population (e.g., chemotherapy increases DFS, which, in turn,
increases overall survival in population A).
These three principles are intended to ensure consistency in
the Whole Disease Model and the economic analyses produced
from it. Such consistency is desirable, however, only if the
underlying model is deemed appropriate by its user(s). Failure
to achieve this may result in multiple consistently inadequate
analyses. A general approach for the Whole Disease Model
development is presented below with the intention of ensuring
that the model conceptualization, implementation, and use are
both appropriate and acceptable.A Five-Stage Process for Developing and Using
Whole Disease Models
Fig. 3 puts forward a general development process for developing
Whole Disease Models. This builds on the five main groups of
model development activity proposed by Chilcott et al. [18]:
1) understanding the decision problem, 2) model conceptualiza-
tion and design, 3) implementation modeling, 4) model checking,
and 5) engaging with the decision.
Stage 1: Understanding the decision problem
The first stage in the Whole Disease Model development process
involves understanding of what is to be modeled, who will use
the model, and the types of economic questions that it will be
used to evaluate. This may be aided by forming a multidisciplin-
ary group to determine those areas where economic analysis may
be most useful and to inform the conceptual basis of the model.
Ideally, this group should ‘‘own’’ the problem, the model, and the
assumptions contained therein [29]. The decision-making con-
text in which the model is developed will influence how this
phase operates. For some decision-making arenas, for example,
the National Institute for Health and Clinical Excellence Technol-
ogy Appraisal Programme, scoping processes may have already
been established, although for others, the scope of potential
service changes and criteria for evaluating these may be unclear.
Formal problem structuring methods, for example, Soft Systems
Methodology and Strategic Options Development and Analysis
(including cognitive mapping) [29], may be useful in generating
Fig. 3 – A five-stage process for Whole Disease Model development and use. PBMA, program-budgeting and marginal
analysis; QALY, quality-adjusted life-year; SSADM, Structured Systems Analysis and Design Method.
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criteria for evaluating service change.
Stage 2: Model conceptualization and design
The second stage involves conceptual development. All models
are based on some conceptualization of the system they are
intended to represent; a formal conceptual model is an explicit
expression of an implicit mental model [18,25]. Given the inevi-
table need for assumptions and simplifications within models, an
implementation model is a subset of the system described by the
conceptual model. This hierarchical separation allows simplifica-
tions represented in the implemented model to be compared
against its conceptual counterpart, thereby allowing for debate
and justification of assumptions and simplifications [18,30]. To
make such comparisons, the conceptual model must be overt.
For the purpose of this framework, conceptual modeling is
defined as the abstraction and representation of complex phe-
nomena of interest in some readily expressible form, such that
individual stakeholders’ understanding of the parts of the actual
system, and the mathematical representation of that system,
may be shared, questioned, tested, and ultimately agreed [30].
These multiple roles can be achieved by separating those
problem-oriented conceptual modeling activities related to
understanding the disease and treatment systems from the
design-oriented conceptual modeling activities related to the
anticipated mathematical structure of the Whole Disease Model.
As such, the development of three conceptual models may be
useful [30]:1) Disease logic models: descriptive problem-oriented models of
underlying disease events and processes including preclinical
and clinical components and transformations between the
two (stage 2a in Fig. 3). These are focused on describing
disease-specific events rather than treatments.2) Service pathways models: descriptive problem-oriented mod-
els of the service pathways used to modify underlying disease
processes (stage 2a in Fig. 3). These are focused on describing
diagnostic and treatment pathways in isolation of diseaseprocesses except where such events influence treatment
decisions (e.g., treatment changes after relapse).3) Structured Systems Analysis and Design Method models [31]:
descriptive design-oriented models that describe interrela-
tionships between disease and treatment systems (stage 2b
in Fig. 3). These models bring together the disease logic and
service pathways models, thereby representing the intellec-
tual and practical leap from model conceptualization to
implementation.
The problem-oriented conceptual models are intended to
establish relevance in terms of the disease and treatment
events/pathways within the system boundary. These are solely
concerned with unearthing the complexity of the system in
which the problem exists as perceived by those individuals who
interact with the service; their role is not to make assertions or
judgments about how those relevant aspects of the disease
process and cancer service should be mathematically repre-
sented. The definition of ‘‘what is relevant?’’ here should reflect
the views of clinical experts, patients, service users, and other
stakeholders and should be expressed without the use of mathe-
matics. Conversely, the design-oriented Structured Systems Ana-
lysis and Design Method model provides a means of drawing
together the problem-oriented conceptual models to consider
alternative implementation model structures, taking into
account the availability and appropriate synthesis of evidence,
feasibility, and the decision-makers’ needs. Thus, the design-
oriented conceptual model is focused on the translation of a
textual/visual description of the system toward a mathematical
solution. Two useful outputs during stage 2b are a visual descrip-
tion detailing how the implemented model will represent the
boundary, breadth, and depth of the disease and treatment
pathways and a list of evidence requirements and potential
sources that may be used to inform the model parameters.
Illustrative examples of these conceptual models are presented
in Appendix 1 found in Supplemental Material at http://dx.doi.
org/10.1016/j.jval.2012.07.008; a practical guide for their develop
ment is available elsewhere [30]. Several other design-related
issues should be considered during stage 2b, including how the
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sources for model calibration, the appropriate choice of modeling
methodology, and anticipated structural relationships between
intermediate and final end points.
Stage 3: Implementation modeling
The third stage involves model implementation. Given the level
of depth and flexibility required to transfer the decision node
across the Whole Disease Model, it is highly likely that
individual-level simulation will be required [32,33]. This may
adopt either a ‘‘next-event’’ or ‘‘time-slicing’’ approach [34]; the
former specifies the time when each competing event is simu-
lated to occur, whereas the latter periodically checks how many
events have occurred within a given interval. Next-event simula-
tion is more accurate and efficient; hence, time slicing should be
avoided unless there is a specific reason for its use (e.g. if patient
trajectories are modeled according to time-dependent risk equa-
tions). Fig. 4 puts forward a generalized next-event programming
approach for Whole Disease Models (this is not software-
specific—the term ‘‘work center’’ relates to the place within the
simulation program in which the entity’s state changes). It should
be noted that this is not a standard queue-based approach.1)TN, 
Fig
truOn model entry, sample patient characteristics (e.g. sex,
disease type, risk subgroup, life expectancy, fitness).2) Route the patient to preclinical state A and sample time to
progression to preclinical state B, time to system entry (e.g.
symptomatic presentation and screening), and update time to
other-cause mortality (life expectancy – current age). Of these
competing events, calculate the time to the next event. Record
which event occurred and route the patient to the preclinical
dummy work center.3) At the preclinical dummy work center, set age ¼ age þ time to
the next event. Examine the last occurring event and route the
patient to the appropriate work center conditional on this
event. If the event was progression, route to preclinical work
center B; if the event was presentation, route to diagnosis; if
the event was death, route the patient to the dead workBirth
FP Route 3: TTNE= system entry e.g. clinical prese
TP
Death due to complication
Model entry point
Set patient characteristics incl. time to 
other-cause mortality
Timestamp model entry age
Preclinical dummy workcentre
Set age = age+TTNE
If TTNE=TTNE1, set route=1
ElseIf TTNE=TTNE2, set route=2
Else set route=n 
Preclinical State A workcentre
Sample TTE1, TTE2, … TTEn
Set TTNE=Min(TTE1, TTE2, …TTEn)
System entry & diagnostic/staging 
pathways
Determine P(TP | histology)
Determine P(FP | histology)
Determine P(TN | histology)
Determine P(FN | histology)
Resample event timings as appropriate
Diagnosed cancer treatmen
model
Determine treatments receive
prognosis given histology and
covariates
. 4 – Generalized simulation programming approach for Whole
e negative; TP, true positive; TTE, time to event; TTNE, time tocenter. If appropriate, resample event times according to the
new disease state of the patient.4) On entry into the cancer service, determine the diagnostic
pathway given the patient’s characteristics (e.g. fitness). Let
the diagnostic pathway determine the probability of positive/
negative findings given the patient’s underlying histology and
test characteristics.5) If the diagnostic outcome is true negative, return the patient
to preclinical work center A. If the diagnostic outcome is false
negative, return the patient to his or her current preclinical
work center (A, B, C, etc.). If the test is false positive, the
patient may progress further along the diagnostic pathway
before achieving a final diagnosis. If the diagnosis is true
positive, route the patient to the treatment model. If the
diagnostic episode results in a state change (e.g. removal of
premalignant lesions), the time to each subsequent event may
need to be resampled.6) On entry into the treatment model, determine pathways
according to underlying histology and other relevant prog-
nostic factors. At this stage, a similar approach may be used to
draw samples for the timing of competing events, using
routing work centers to examine which event occurs first, to
determine subsequent pathways given that event, and to
assign costs and health outcomes for the interval relating to
that event.
Placement of decision nodes within the model
The appropriate placement of decision nodes across the model
will depend on the options for service change to be evaluated and
the disease area under consideration. Generally speaking, these
can be placed in four ways: the decision node may alter 1) the
route for a given subgroup; for example, the patient is routed to
diagnostic test B rather than test A; 2) the time-to-event curve
applied for a given event; for example, the patient’s disease-free
interval is sampled from DFS curve D rather than DFS curve C; 3)
the probability of one-off events; for example, reduce the
patient’s risk of operative mortality; or 4) costs and/or utilityRoute 1: TTNE=Death
Route 2: TTNE=progression
REPLICATED 
STRUCTURE 
FOR 
REMAINING
PRECLINICAL 
MODEL
ntation or scheduled screening
FN
Death due to cancer / other causes
s
Preclinical State B workcentre
Sample TTE1, TTE2, … TTEn)
Set TTNE=Min(TTE1, TTE2, …TTEn)
Death workcentre
Timestamp model death age
t pathways 
d and 
/or other 
Disease Models. FN, false negative; FP, false positive; TN,
next event.
VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 1 2 7 – 1 1 3 6 1133with no change in pathways followed by the particular patient
subgroup.
Model calibration
The framework requires that the model includes a representation
of the preclinical natural history. These preclinical processes
cannot typically be directly observed, because patient outcomes
are usually confounded by interventions used to modify disease
course at the point of detection or by ethical constraints asso-
ciated with the risk of harms of repeated observation. Conse-
quently, calibration methods are required to estimate parameters
describing patient trajectories through the preclinical model by
fitting these against external observable data (e.g. disease stage
and disease incidence). Numerous calibration approaches exist,
including manual and probabilistic methods [35] and more
complex metaheuristics (including Markov chain Monte Carlo
methods such as simulated annealing [25] and the Metropolis-
Hastings algorithm [36,37]). The latter approaches allow for the
explicit representation of correlations between unobservable
parameters and provide more meaningful descriptions of uncer-
tainty. These methods are, however, difficult to implement and
require both specialist statistical input and considerable compu-
tation time. Irrespective of the approach selected, decisions will
be required concerning the target data sets against which to fit
the model, the criteria used to determine goodness of fit, and the
heuristic elements of the calibration algorithm [38].
Discounting
Time-slice models usually incorporate time preferences for the
costs and outcomes of events during the period in which they
occur by using the standard discounting formula [39]:
V0 ¼ Vt
1
ð1 þ rÞt ð3Þ
where V0 is the equivalent current value at time zero, Vt is the
value at time t, and r is the discount rate.
This approach is appropriate for discounting most resource
costs within a Whole Disease Model on the basis of the time at
which each resource is consumed by individual patients. The
appropriate discounting of health outcomes requires a different
approach. Eq. 3 is equivalent to an exponential survival function
whereby the hazard rate l is equal to ln(1 þ r). For a definite
integral beginning at time t0 (birth) and ending at time t3 (death)
for a given patient, discounted survival is given by Eq. 4. Assum-
ing health-related quality of life differs across three mutually
exclusive time intervals—no cancer [t1  t0], premalignant
disease [t2  t1], and cancer [t3  t2]—discounted QALYs for
each patient would be calculated by using Eq. 5.
LYGs ¼
Z t3
t0
e  ltdt ¼
X 1
 l e
 lt1  1 le
 lt0
 
,

1
 l e
 lt2  1 le
 lt1
 
,
1
 l e
 lt3  1 le
 lt2
 
ð4Þ
QALYs ¼ q
Z t3
t0
e  ltdt ¼
X
q1 
1
 le
 lt1  1 le
 lt0
 
,

q2 
1
 le
 lt2  1 le
 lt1
 
,
q3 
1
 le
 lt3  1 le
 lt2
 
ð5Þ
where q is a valuation of health-related quality of life for the
health state, t is time, and l is the instantaneous discount rate.
This continuous discounting approach is generally not appro-
priate for discounting costs, especially those that tend to belumpy where resources are consumed unevenly over time, for
example, follow-up regimens after tumor resection.
Handling variability and parameter uncertainty
As the proposed simulation approach described here does not
involve patients competing for resources within a system with
finite capacity, the state of the model system is independent of
the patients running through it; hence, the usual simulation
approach of running multiple trials using different random
number seeds is unnecessary. It is important, however, to ensure
that sufficient patients are simulated to ensure that the results
are robust regardless of the random numbers generated. The
model should be evaluated by using expected estimates of costs
and outcomes through standard probabilistic methods.
Stage 4: Model checking
Model checking activity should take place throughout the Whole
Disease Model development process. Table 1 details methods for
avoiding and identifying errors; this builds on the work of
Chilcott et al. [18], with a specific focus on Whole Disease Models.
Stage 5: Engaging with the decision
The final stage involves engaging with the decision. Whole
Disease Models allow for the economic analysis of alternative
service changes by using a range of decision rules including 1)
conventional threshold-based cost-utility analysis; 2) Sendi,
Birch, and Gafni’s ‘‘step in the right direction’’ approach [6]; 3)
microlevel PBMA [7]; and 4) disease-level constrained optimiza-
tion. These are outlined below.
Decision approach 1: Piecewise threshold-based cost-utility
analysis
Conditions for use. Competing decision alternatives a1, a2,y, an
exist at a single point in the pathway. The cost-effectiveness
threshold (l) is assumed to be fixed and known.
Whole Disease Model evaluation approach1) Identify competing decision alternatives a1, a2, y, an at a
single point in the service pathway, where a1 is the standard
treatment.2) Generate expected costs and QALYs for a1.
3) Respecify the model parameter set given for alternatives
a2, y, an.
4) Generate estimates of expected costs and QALYs for a2,y, an.
5) Calculate the incremental cost-effectiveness ratio for each
option versus the next best nondominated alternative by
using standard rules [40] and compare against threshold l.
Decision approach 2: Piecewise investment/disinvestments
Conditions for use. Competing decision alternatives a1, a2,y, an
exist at a single point in the pathway. The budget is assumed to
be constrained at the current level of expenditure.
Whole Disease Model evaluation approach1) Identify competing investment alternatives a1, a2, y, an for
service investment at a single point in the pathway, where a1
is the current standard treatment.2) Generate estimates of expected cost and QALYs for a1.
3) Respecify model parameter set given for alternatives a2,y, an.
4) Generate estimates of expected cost and QALYs for a2, y, an.
5) Generate incremental cost-effectiveness ratio according to
standard rules and compare against threshold l.
Table 1 – Processes and techniques for avoiding identify-
ing errors within Whole Disease Models.
Suggested activities for avoiding errors within Whole Disease
Models
Ensuring mutual understanding between modelers and problem owners
 Use formal problem structuring methods to understand the
problem situation, decision-makers’ objectives, and clinical
intent of interventions across the system
 Develop disease logic models and service pathways models in
conjunction with clinical experts who practice within the dis-
ease service
 Iterative negotiation and communication between the modeler
and the client
Checking face validity of the model
 Establish ongoing long-term involvement with stakeholders
who know about the disease and its treatment
 Peer review of conceptual models
 Discuss data sources with clinicians
 Step through simulation model pathways with clinicians
 Ask clinicians to provide feedback on whether results meet their
expectations
 Compare interim or final model results against predetermined
expectations (from previous models and from skeleton/back-of-
the-envelope model)
Transparency of methodology and assumptions
 Written and diagrammatic description of conceptual models
 Explicit agreement of problem-oriented conceptual models
before developing SSADM
 Development of written design-oriented SSADM model plus
consultation
 Transparent and iterative comparison of design-oriented
SSADM with problem-oriented conceptual model
Housekeeping techniques
 Use of a standard model layout
 Consistent programming approach using routing work centers
(see stage 3 description)
 Use of separate referencable model parameters worksheet
within simulation package
 Use of identifiers that distinguish between labels, distributions,
and work centers, for example, ‘‘label name lbl’’ and ‘‘distribution
name dst’’
Suggesting activities for error checking within Whole Disease
Models
Model testing
 Compare point estimates against the expectation of the means
for each parameter
 Use a.CSV file to derive logical tests (e.g., check time of death is
less than or equal to life expectancy)
 Check data used in the model against source material
 Check the integrity of all premodel analysis
 Construct mock-ups in MS Excel for portions of the simulation
that are difficult to assess
 Annotate all routing code to aid ‘‘stepping through’’ processes
 Test model logic by stepping through the experience of indivi-
dual patients
 Insert dummy states and examine throughput by using specific
patient labels or global numbers
 Record interim outputs (numbers of patients and time to events)
within work centers to check model flows and event times are
as intended
 Check model results against expectations (and ensure that
unexpected results can be explained)
 Compare deterministic and probabilistic model results
Model peer review
 Internal peer review by the modeler responsible for building
the model
 Internal peer review by the modeler not involved in developing
the model
 External peer review by clinical experts and methodologists
 Check model input values against the source material
SSADM, Structured Systems Analysis and Design Method.
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effectiveness ratio4 0, identify intervention b1 elsewhere in
the pathway in which service disinvestment may be possible
and identify disinvestment option b2.7) Respecify model parameter set given for alternatives with a1,
a2, y, an 9 b2.8) Generate estimates of expected cost and QALYs for a2,y, an 9 b2.
9) Repeat steps 6 to 8 until incremental costr 0 and incremen-
tal QALYs4 0.
Note if the condition set within step 9 cannot be met given
alternatives a1, a2,y, an and disinvestment option b2, then either
an alternative disinvestment option should be sought or alter-
natives a2, y, an should be abandoned.
Decision approach 3: Disease-level PBMA
Conditions for use. Investment and disinvestment options exist
at multiple points in the pathway. The budget is constrained at
some level, current or otherwise.
Whole Disease Model evaluation approach1) Identify potential investment and disinvestment alternatives
across the breadth of the service pathway (options may arise
during problem structuring by mapping out the service pathways
or from experimentation by using the implemented model).2) Generate estimates of expected cost and QALYs for the base-
line service configuration.3) Repeat step 2 for each alternative configuration.
4) Use disaggregated cost and outcome information as a direct
input into the wider PBMA decision process.
Decision approach 4: Disease-level constrained optimization
Conditions for use. Investment and disinvestment options exist at
multiple points in the pathway, and the combination set is very
large. The budget is constrained at some level, current or otherwise.
Whole Disease Model evaluation approach1) Identify portfolio of potential investment and disinvestment
alternatives across the entire service, as described in approach 3.2) Use a genetic algorithm or another evolutionary programming
algorithm to search through the decision space to identify
best configurations of the disease service, specifying adher-
ence to the budget as a constraint of the acceptability criteria.
Given inevitable limitations in evidence, true optimization of the
service is unlikely to ever be possible. Nevertheless, an intermediate
approach would involve identifying a finite set of options and
restricting the search algorithm to this decision space.Discussion
This article has put forward a methodological framework for
developing models that represent whole disease and treatment
pathways. We have argued that this approach can provide a
means of overcoming many of the shortcomings of conventional
piecewise economic evaluation through 1) avoiding inconsisten-
cies between analyses through the development of a single
coherent model, 2) explicitly capturing relevant knock-on
impacts of upstream and downstream technologies elsewhere
in the pathway upon the intervention under consideration, and 3)
opening up flexibility concerning how the model is used through
the adoption of alternative economic decision rules such as
disease-level constrained maximization. Once such a Whole
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is likely to require considerably less time than the development of
multiple de novo piecewise models. These benefits have been
demonstrated though only in a small number of case studies
[41]. Although these potential benefits are appealing, the initial
development of a Whole Disease Model requires a nontrivial
investment of time and human resource. The development of
models on this scale has implications for the identification,
selection, and use of evidence as well as a greater burden on the
modeler to understand current and best practice across a whole
clinical disease area. The burden for model checking may also be
increased. Related to this, the approach inevitably requires the use
of specialist statistical calibration methods; these methods are
complex, and there remains little consensus within the literature
regarding how to design and undertake this process. Furthermore,
it could, in principle, be possible to capture upstream impacts
within a conventional piecewise model by using simple sensitivity
analysis (although determining the plausibility of such impacts is
difficult and rarely done in practice). It is also possible that multiple
parties could develop their own Whole Disease Models, each of
which may involve the use of different structures, assumptions,
and evidence. Given these trade-offs, one must be pragmatic in
deciding whether to adopt this system-level modeling approach;
there may be little point in incurring these costs if the benefits of
Whole Disease Modeling are not required; in such situations, one
may prefer a series of piecewise models.
The value of Whole Disease Modeling may be realized when
one or more of the following issues are present:1) Multiple options for service change require formal economic
analysis at a single time point (e.g. within clinical guideline
development).2) Services are subject to rapid innovation; hence, the value of
Whole Disease Modeling may be iteratively realized through
the reuse of the model across multiple decision problems at
different points in time.3) A substantial proportion of currently provided services within
a disease pathway have not previously been subjected to
formal economic analysis.4) There is an a priori belief that potential knock-on impacts of
upstream aspects of the system may influence the decision
problem under consideration.5) The adoption of a simple cost per QALY decision rule fails to
reflect the complexity of the decision-makers’ objectives, for
example, joint investment and disinvestment.
In these instances, Whole Disease Modeling may provide a more
coherent approach for informing resource allocation decisions.
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